null

Zolbetuximab Biosimilar (Anti-CLDN18.2) Antibody (HDBS0069)

SKU:
HDBS0069
Antibody Type:
Biosimilar Reference Antibody
Applications:
IHC
FC
Drug Development
Pharmacokinetics
Disease Area:
Cancer
Protein:
CLDN18.2
Reactivity:
Human
Host Species:
Humanized
Isotype:
IgG1
€399

Description

system_update_altDatasheet

Zolbetuximab (Anti-CLDN18.2) Biosimilar Antibody (HDBS0069)

The Anti-CLDN18.2 (Zolbetuximab Biosimilar) Antibody (HDbs0069) is a valuable tool for researchers studying CLDN18.2, a tight junction protein involved in maintaining epithelial barrier integrity. This monoclonal antibody, produced in mice, exhibits high specificity and sensitivity for detecting CLDN18.2 in various samples, making it suitable for use in immunohistochemistry and flow cytometry applications.CLDN18.2 is known to be overexpressed in certain cancers, particularly gastric cancer, where it serves as a potential therapeutic target.

By targeting CLDN18.2, researchers can investigate the role of this protein in cancer progression and explore novel treatment strategies. The Anti-CLDN18.2 Antibody (HDbs0069) provides researchers with a reliable tool for investigating the biological function of CLDN18.2 and its potential as a target for precision medicine approaches in cancer therapy.